证券简称：国新健康 证券代码：000503 编号：2023-34 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特此公告。 (参会报名二维码) 国新健康保障服务集团股份有限公司（以下简称"公司"）于 2023 年 4 月 27 日在巨潮资讯网（http://www.cninfo.com.cn）披露了《2022 年年度报告》及其 摘要。为使投资者及时了解公司经营情况，公司将于 2023 年 5 月 18 日（星期 四）下午 15:00 至 16:00 通过电话会议方式举行 2022 年度业绩说明会。电话会 议拨入方式如下，请扫描下方二维码报名参会： | 地点 | | 会议拨入号码 | | --- | --- | --- | | 中国内地 | | 400 810 8228 / +86 1058084199 | | 中国香港 | | +852 30051355 | | 参会密码: | 12873957 | | 出席本次说明会的公司人员有：党委副书记、董事、总经理李永华先生，独 立董事王秀丽女士，党委委员、副总经理袁洪泉先生，党委委员、总会计师王文 长先生，董事会秘 ...

Financial Performance - The company reported a total revenue of RMB 1,500,000 from the procurement of hardware and software services under the health assistance project with the Li Chuan Health Bureau[35]. - The company's operating revenue for 2022 was ¥311,079,455.60, representing a 23.19% increase from ¥252,515,004.56 in 2021[162]. - The net profit attributable to shareholders for 2022 was -¥84,471,751.01, a 51.96% improvement compared to -¥175,821,833.40 in 2021[162]. - The cash flow from operating activities for 2022 was -¥160,204,210.35, which is a 52.84% decline from -¥104,821,324.48 in 2021[162]. - The total assets at the end of 2022 were ¥1,104,696,713.12, down 7.35% from ¥1,192,309,580.42 at the end of 2021[162]. - The net assets attributable to shareholders decreased by 9.45% to ¥711,368,370.48 at the end of 2022 from ¥785,613,339.24 at the end of 2021[162]. - The basic earnings per share for 2022 improved to -¥0.0931, a 52.31% increase from -¥0.1952 in 2021[162]. - The company reported a significant reduction in non-recurring losses, with a total of ¥33,340,289.65 in non-recurring gains for 2022 compared to ¥13,493,588.30 in 2021[165]. - The company received government subsidies amounting to ¥950,254.35 in 2022, up from ¥536,998.98 in 2021[165]. Shareholder Information - The actual payment amount for the remuneration of directors, supervisors, and senior management during the reporting period was 10.6249 million yuan[1]. - The total number of shares decreased from 907,215,204 to 906,413,204, reflecting a reduction of 802,000 shares[39]. - The company’s limited shares decreased from 8,393,000 (0.93%) to 7,591,000 (0.84%) due to the reduction in holdings[39]. - The company has a total of 72 middle and senior management personnel and core employees, with a total of 8,393,000 shares granted under the incentive plan[67]. - The largest shareholder, China Oceanwide Holdings Group Co., Ltd., holds 26.00% of the shares, totaling 235,702,593 shares[91]. - The total number of common shareholders at the end of the reporting period was 58,456, an increase from 57,745 at the end of the previous month[87]. - The company has committed to not reducing its holdings in the newly issued shares for a period of six months following the completion of the private placement, which is expected to enhance shareholder confidence[1]. - The company has confirmed that the funds used for the subscription of the new shares will come entirely from legal self-owned or self-raised funds, ensuring no structured financing arrangements are involved[1]. - The company has stated that there are no plans to provide financial assistance or guarantees to investors participating in the private placement, maintaining compliance with regulatory requirements[1]. Corporate Governance - There were no significant internal control deficiencies identified during the reporting period, ensuring the protection of the interests of the company and all shareholders[8]. - The company has completed the election of the board of directors and supervisory board, appointing senior management during the reporting period[32]. - The company’s board and supervisory board have undergone re-election to ensure effective decision-making[129]. - The company’s financial report has been confirmed as true, accurate, and complete by its responsible persons[135]. - The company has not reported any changes in accounting policies or significant accounting errors during the reporting period, ensuring the integrity of its financial statements[41]. Regulatory Compliance - The company did not receive any administrative penalties due to environmental issues during the reporting period[12]. - The company has committed to strictly adhering to regulatory guidelines and maintaining transparency in its operations, which is crucial for investor trust[1]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties during the reporting period[21]. - The company has not faced any penalties or rectification issues during the reporting period[132]. - The company has no financial transactions with related financial companies during the reporting period[121]. Business Operations - The company’s strategic focus includes high-tech product development, sales, and consulting services, as well as investment consulting and real estate development[73]. - The company focuses on four main business segments: digital medical insurance, digital healthcare, digital pharmaceuticals, and health services[181]. - The digital medical insurance segment aims to support the reform of medical insurance payment methods and improve the efficiency of medical fund usage[181]. - The company has implemented a DRG (Diagnosis-Related Group) payment service, enhancing the management of medical insurance funds and promoting quality-based payment systems[181]. - The introduction of big data and AI technologies has improved the efficiency of medical fund monitoring and fraud detection[189]. - The company is committed to building a comprehensive medical insurance credit supervision system, enhancing the regulatory environment for medical insurance[190]. - The national policies, including the "Data Twenty Articles," provide new opportunities for the company's business development and strategic planning[180]. - The company aims to become a leader in digital medical insurance and a builder of digital healthcare and pharmaceuticals[183]. - The company is focused on sustainable business development, leveraging data value and innovative mechanisms[183]. Related Party Transactions - The company has engaged in related party transactions with its wholly-owned subsidiary Guoxin Limited, as disclosed in previous announcements[79]. - The company reported no significant related party transactions during the reporting period[96]. - The company has a non-operating related party debt of 164.24 million RMB, with no new additions or repayments during the reporting period[120]. - The company has maintained a stable interest rate of 0.00% on related party debts[120]. Stock Repurchase - A total of 802,000 restricted stocks were repurchased and canceled due to the disqualification of 7 incentive objects from the stock incentive plan[5]. - The company repurchased 802,000 shares, which represents 0.09% of the total share capital, for a total amount of approximately 40.58 million RMB[76]. - The company’s stock repurchase plan is aimed at canceling shares to enhance shareholder value and does not affect the control structure of the company[86]. - The actual controller of the company remains unchanged after the stock repurchase, with China Guoxin Holdings Co., Ltd. continuing as the actual controller[86]. - There were no major contracts or leasing situations during the reporting period[97][98].

Financial Performance - Total operating revenue for Q1 2023 was ¥55,766,199.77, an increase of 47.0% compared to ¥37,951,381.37 in Q1 2022[11] - Total operating costs for Q1 2023 were ¥99,793,458.91, up 23.5% from ¥80,759,723.77 in the same period last year[11] - The company reported a net loss of ¥43,123,912.80 for Q1 2023, an improvement from a net loss of ¥49,421,999.82 in Q1 2022[11] - The net profit for the current period is -43,866,780.96, compared to -49,422,023.57 in the previous period, showing an improvement[14] - The total comprehensive income for the current period is -44,125,283.59, compared to -49,442,066.65 in the previous period[14] - Basic and diluted earnings per share are both -0.0484, an improvement from -0.0545 in the previous period[14] - Net loss attributable to shareholders was ¥-43,865,115.01, improving by 11.25% from ¥-49,423,957.16 year-over-year[27] Cash Flow and Liquidity - Cash and cash equivalents decreased to ¥116,974,970.15 from ¥169,465,147.63 at the beginning of the year, a decline of 30.9%[3] - The net cash flow from operating activities is -83,500,999.68, an improvement from -101,791,799.62 in the previous period[19] - Cash inflows from operating activities totaled 48,705,936.60, up from 23,618,915.13 in the previous period[19] - Cash outflows from operating activities increased to 132,206,936.28 from 125,410,714.75 in the previous period[19] - The ending cash and cash equivalents balance is 112,821,001.03, down from 238,032,127.40 in the previous period[21] Assets and Liabilities - Total assets decreased to ¥1,063,525,048.13 from ¥1,104,696,713.12, a reduction of 3.7%[10] - Total liabilities increased slightly to ¥393,847,260.24 from ¥391,707,776.39, reflecting a 0.5% rise[7] - The company’s equity attributable to shareholders decreased to ¥668,058,887.59 from ¥711,368,370.48, a decline of 6.1%[7] - Total assets at the end of the reporting period were ¥1,063,525,048.13, a decrease of 3.73% from ¥1,104,696,713.12 at the end of the previous year[27] Research and Development - Research and development expenses for Q1 2023 were ¥967,945.83, down 52.5% from ¥2,042,652.21 in Q1 2022[11] - Research and development expenses decreased by 52.61% to ¥967,945.83, reflecting differences in project stages[32] Market Strategy and Future Plans - The company plans to focus on market expansion and new product development in the upcoming quarters[12] - Sales expenses increased by 77.33% to ¥8,515,293.56, driven by enhanced market expansion efforts[32] Shareholder Information - The total number of common shareholders at the end of the reporting period is 57,745, with the largest shareholder, China Oceanwide Holdings, holding 26.00% of shares, equating to 235,702,593 shares[37] - The second largest shareholder, Jiao Yu, holds 1.03% of shares, amounting to 9,299,444 shares, while Hong Kong Central Clearing Limited holds 1.02% with 9,256,810 shares[37] Investments and Financing - The company experienced a 100% increase in short-term borrowings, totaling ¥90,113,307.28, due to new bank credit loans[32] - The net cash flow from financing activities is 43,866,996.67, compared to -715,521.65 in the previous period[21] - The company received government subsidies amounting to ¥312,113.78, primarily due to personal income tax refunds[29] - Investment income was reported at ¥335,268.91, a significant turnaround from a loss of ¥-537,717.96 in the previous year, due to profit recognition from equity method accounting[32] Contractual Adjustments - A contract adjustment was made for a software development project, reducing the total price from RMB 13,082,300 to RMB 12,432,300[43] - The company has decided to waive its preemptive rights for capital increase in its associate company, Beijing Yiyong Technology Co., Ltd.[44]

编号：20150107－01 证券代码：000503 证券简称：海虹控股 海虹企业（控股）股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-----------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 招商证券：黄斐玉 | | | 人员姓名 | | | | 时间 | 2015 年 1 月 7 日 | | | 地点 | 北京 | | | 上市公司接待人 | 董事会秘书：肖琴 | | | 员姓名 | | | | 投资者关系活动 | 投资者互动交流： | | | 主要内容介绍 | 1 、关于业务进展情况 | | | | 目前公司已在 20 | 个省/直辖市的百余地市 ...

编号：20150107－01 证券代码：000503 证券简称：海虹控股 海虹企业（控股）股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-----------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 招商证券：黄斐玉 | | | 人员姓名 | | | | 时间 | 2015 年 1 月 7 日 | | | 地点 | 北京 | | | 上市公司接待人 | 董事会秘书：肖琴 | | | 员姓名 | | | | 投资者关系活动 | 投资者互动交流： | | | 主要内容介绍 | 1 、关于业务进展情况 | | | | 目前公司已在 20 | 个省/直辖市的百余地市 ...

编号：20150212－02 证券代码：000503 证券简称：海虹控股 海虹企业（控股）股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 嘉实基金：季文华 渤海证券：王雯 华夏人寿：胡朝凤 | | 人员姓名 | 华创证券：张伟光、彭婷 | | | 时间 | 2015 年 2 月 12 日 | | | 地点 | 北京 | | | 上市公司接待人 | 董事会秘书：肖琴 | | | 员姓名 | | | | 投资者关系活动 | 投资者互动交流： | | | 主要内容介绍 | 1 、控费业务进展情况 ...